SEC Comment Letter for Arcadia Biosciences, Inc. (RKDA) (CIK 0001469443) (RKDA) — Dec 17, 2019
Arcadia Biosciences, Inc. (RKDA) (CIK 0001469443)
Date: Dec. 17, 2019 · CIK: 0001469443 · Accession: 0000000000-19-016499
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-235446
Letter
December 17, 2019 Matthew T. Plavan Chief Executive Officer Arcadia Biosciences, Inc. 202 Cousteau Place, Suite 105 Davis, CA 95618 Re:Arcadia Biosciences, Inc. Registration Statement on Form S-1 Filed December 11, 2019 File No. 333-235446 Dear Mr. Plavan: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Ada D. Sarmento at 202-551-3798 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Michael De Angelis, Esq.
Show Raw Text
December 17, 2019
Matthew T. Plavan
Chief Executive Officer
Arcadia Biosciences, Inc.
202 Cousteau Place, Suite 105
Davis, CA 95618
Re:Arcadia Biosciences, Inc.
Registration Statement on Form S-1
Filed December 11, 2019
File No. 333-235446
Dear Mr. Plavan:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Ada D. Sarmento at 202-551-3798 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Michael De Angelis, Esq.